← Eichor
Study identifier: NCT06563323 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)

Condition: Pyoderma Gangrenosum · Skin Diseases · Wound Heal  ·  Sponsor: Oregon Health and Science University

PhasePhase 2
Planned participants17
Who can joinAll sexes, 18 Years to 99 Years
Healthy volunteersNo

About this study

A single-arm open-label study assessing short-term (week 6, 16) and long-term (week 32) efficacy of guselkumab in adult participants with pyoderma gangrenosum (PG)

This description comes directly from the study's public registry record.

Talk to the study team

Alex G Ortega-Loayza, MD, MCR  ·  503-418-3376  ·  ortegalo@ohsu.edu

Always discuss trial participation with your own doctor first.

Locations (2)

Ohio State DermatologyColumbus, Ohio, United StatesRecruiting
Oregon Health and Science UniversityPortland, Oregon, United StatesNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06563323